The best stocks to watch tomorrow are not the ones every headline is chasing. Thursday, Oct. 22 was a lopsided session: the Nasdaq fell 2.6% for its steepest drop since early June on renewed AI-spending fears while the Dow finished flat, and the rotation left a stack of earnings-driven gaps for Friday, Oct. 23. RingCentral is up roughly 15% after hours, Kaiser Aluminum is 23% lower, Western Digital and Deckers are sliding on guidance, Biohaven is rebounding on an FDA review date, and a penny diagnostics name is spiking on Medicare cash. Gentex and Booz Allen report before the open. Here are ten stocks to watch tomorrow, each with a full data table, support and resistance, a bull and bear case, and a forecast.
Stocks to Watch Tomorrow: Thursday’s Market Snapshot as AI Fears Slam the Nasdaq
| Index / Asset | Thursday, Oct. 22 Close | Day | Wednesday Close |
|---|---|---|---|
| S&P 500 | 7,663.43 | -1.21% (-93.74) | 7,757.17 |
| Nasdaq Composite | 26,008.86 | -2.60% (-694.00) | 26,702.86 |
| Dow Jones Industrial Average | 52,867.98 | +0.02% (+11.89) | 52,856.09 |
| Russell 2000 | About 2,781.97 | About +0.02% | n/v |
| Brent crude | Above $110 | Higher | n/v |
| Bitcoin | About $81,700 | Lower | About $84,000 |
A batch of high-profile AI-related earnings reignited fears about the spending race, with microchips leading the Nasdaq lower. Breadth told the story: 2,766 Nasdaq stocks fell against 2,022 that rose, and the NYSE logged 366 new lows against 173 new highs. S&P 500’s worst day since July and a sharp drop in the 10-year Treasury yield that lifted homebuilders, banks and REITs.
Macro drivers for Friday:
- AI spending doubts: Meta fell about 7% despite an earnings beat, Tesla slid about 3%, and Marvell, KLA and AMD each dropped 8% to 9%.
- Oil: Brent pushed above $110 on fresh Houthi attacks on Saudi targets, a tailwind for energy and a headwind for airlines and consumer names.
- Power stocks: Bloom Energy fell 8.7% to $217.77 despite a record quarter and a raised $4.4B to $4.6B revenue guide. TNN broke down its setup in Thursday’s stocks-to-watch list, so it is not repeated below.
- Next catalysts: The Fed meets Oct. 27-28 (see TNN’s October Fed rate hike explainer), and Microsoft and Alphabet report Oct. 28.
Data note: Closes are Oct. 22 regular-session prints where available. Figures marked “about” are derived from reported percentage moves or after-hours quotes, and “n/v” means not verified. After-hours prices move quickly and are shown as ranges. Support and resistance levels are analytical zones, not guarantees.
Stocks to Watch Tomorrow: Friday’s Earnings Calendar and After-Hours Movers
| Timing | Names | What matters |
|---|---|---|
| Reported Thursday after the close | RNG, WDC, DECK, RHI, BE | Gap reactions at the open |
| Reported Wednesday after the close | KALU | Follow-through after a 23% drop |
| Before the open Friday | BAH (call 8:00 a.m. ET), GNTX (call 9:30 a.m. ET), AXP, SLB, INFY, ALV, FLG | Guidance and federal, auto and energy read-throughs |
| News-driven | BHVN, LUCD, SAIQ | FDA review date, Medicare payments, space momentum |
1. RingCentral (RNG) | Last Close $79.42 (-3.64%) | Q3 Beat, Up 14% to 15% After Hours
A Cloud-Phone Stock Up 165% in a Year Punches Through Its 52-Week High After the Bell
Catalyst & latest news: RingCentral reported third-quarter results after the close: revenue of $676 million (+5.9%), subscription revenue of $653 million (+6.0%) and record operating margins. Non-GAAP EPS of $1.33 beat the roughly $1.28 estimate, and management raised full-year non-GAAP EPS guidance to $5.07 to $5.12 and free cash flow guidance to $620M to $630M. The company also named the Golden State Warriors’ agentic-AI voice partner, per ChartMill’s after-hours roundup.
Technicals: RNG closed at $79.42 after slipping from $82.42, just under its prior 52-week high of $83.72, so the after-hours quote of roughly $89 to $91.50 would be a breakout to fresh highs. The stock was already hugging that high before the print. After-hours liquidity is thin, so the move may not hold at the open.
Fundamentals: AI products now make up about 15% of annual recurring revenue (more than $400M), double a year ago. Non-GAAP operating margin reached 24.7%, free cash flow was $157M (23.2% of revenue), and gross debt is below $1B. Q4 EPS guidance of $1.32 to $1.37 is close to the Street’s roughly $1.36.
.
| Metric | Data |
|---|---|
| Last close / prior close | $79.42 (-$3.00, -3.64%) / $82.42 |
| After-hours | About $89.30 – $91.50 (+12% to +15%) |
| 52-week range | About $24 – $83.72 (before after-hours) |
| Market cap | About $7.0B (87.7M diluted shares, derived) |
| P/E | About 15.6x forward (guided EPS midpoint $5.10) |
| Dividend | $0.125 quarterly (about 0.6% yield), payable Nov. 20 |
| Volume vs. average | n/v |
| Performance | About +165% over 12 months |
| Q3 EPS / revenue | $1.33 vs. about $1.28 est. / $676M (+5.9%) |
| 2026 guidance | Non-GAAP EPS $5.07 – $5.12; free cash flow $620M – $630M |
| Short interest | About 9% of float (August) |
| Analysts | Mostly Hold; latest published targets near $40 – $55 sit far below the price |
| Support (S1 / S2 / S3) | $83.72 / $79.42 / $75 |
| Resistance (R1 / R2 / R3) | $91.50 / $95 / $100 |
Scenarios: Bullish: a gap that holds above $83.72 opens $95 to $100. Base: a gap up that fades toward $83 to $88. Bearish: a lost $79.42 closes the gap entirely.
Bull case: Raised profit guidance, record margins, doubling AI revenue and a stock still trading near 16x forward earnings. Bear case: Revenue growth is only about 6%, the Q4 EPS guide is a touch light, short interest is elevated and the stock has already multiplied.
What to watch:
- Whether the open holds above the old $83.72 high
- Analyst target hikes, which sit far below the price
- Volume versus the thin after-hours session
Forecast: Holding $83.72 keeps $91.50 to $95 in play. A fade under $79.42 wipes out the reaction.
Why this matters: RingCentral is a clean test of whether profit-driven software beats can pull money back into tech on a day when AI hardware was being sold.
2. Western Digital (WDC) | Last Close $354.19 (-6.43%) | Blowout Quarter, Stock Still Falls
A 55% Revenue Surge and a 17% Dividend Raise, Met With a 6% Selloff
Catalyst & latest news: Western Digital’s fiscal first-quarter report showed revenue of $4.38B (+55%), non-GAAP EPS of $4.64 against roughly $4.10 expected, and free cash flow of $1.38B. It guided Q2 revenue up 66% to 72% and EPS to $5.80 plus or minus $0.20 versus about $4.82 expected, and raised the quarterly dividend 17% to $0.175. The stock still slipped after hours because of the day’s AI-trade selling.
Technicals: WDC closed at $354.19 after a $353.99 to $367.34 range and traded near $330 to $335 after hours, according to StockAnalysis. That is close to the 50-day low of about $332 flagged by MarketBeat. The stock sits roughly 56% below its $799.87 high.
Fundamentals: Non-GAAP gross margin was 58.1% and operating margin 49.1%, with non-GAAP EPS up 161% year over year. Management said capex should run slightly above 4% to 6% of revenue over the next two years.
.
| Metric | Data |
|---|---|
| Last close / prior close | $354.19 (-$24.32, -6.43%) / $378.51 |
| Day’s range | $353.99 – $367.34 |
| After-hours | About $330 – $335 (-5.6% to -6.7%) |
| 52-week range | $117.23 – $799.87 |
| Market cap | About $132.6B |
| P/E (TTM) | About 14.6x (EPS $24.28, derived) |
| Dividend | $0.175 quarterly, raised 17% (about 0.2% yield) |
| Volume vs. average | n/v |
| Beta | 2.11 |
| Q1 EPS / revenue | $4.64 vs. about $4.10 est. / $4.38B (+55%) |
| Q2 guidance | Revenue +66% to +72%; EPS $5.80 ± $0.20 vs. $4.82 consensus |
| Analysts | Strong Buy (22 Buy, 4 Hold); average target about $657; range $420 – $1,050 |
| Support (S1 / S2 / S3) | $331 / $300 / $250 |
| Resistance (R1 / R2 / R3) | $354.19 / $367.34 / $378.51 |
Scenarios: Bullish: guidance-led buyers reclaim $367 and the prior close at $378.51. Base: a choppy gap-down that bases near $331 to $345. Bearish: a break of $331 opens $300.
Bull case: Accelerating revenue, near-50% operating margins, a higher dividend and a guide far above consensus. Bear case: Beta above 2, a stock down by more than half from its high, AI-trade selling that ignored the beat and a valuation debate that has not gone away.
What to watch:
- Whether the $331 to $332 zone holds at the open
- Analyst target changes after the guide
- Moves in peers and the broader AI-hardware trade
Forecast: Holding $331 allows a bounce toward $354 to $367. A break likely tests $300.
Why this matters: Western Digital is the cleanest example of a company beating on every line while the stock follows the AI-sentiment tape instead.
3. Deckers Outdoor (DECK) | Last Close About $85.30 | Revenue Miss, Down 7% to 8% After Hours
HOKA Slows, UGG Stalls and a Tariff Refund Props Up the EPS Beat
Catalyst & latest news: Deckers reported fiscal Q2 revenue of $1.481B (+3.5%), short of the $1.51B estimate, while EPS of $2.31 beat the $1.80 consensus. Benzinga reported full-year revenue guidance was cut to $5.70B to $5.73B versus $5.88B expected, while EPS guidance rose to $7.80 to $7.95. 247/7 Wall St. pointed out that a one-time tariff refund added about $0.28 to the quarter and roughly $0.52 to the year.
Technicals: DECK traded near $78.22 after hours, down 8.3% per Finchannel’s report, which implies a regular close near $85.30. That after-hours price sits right at the 52-week low of $78.91.
Fundamentals: HOKA sales rose 6.8% to $677.2M and UGG 3.5% to $786.4M, but direct-to-consumer comparable sales fell 6.4%. Gross margin was 60.5% versus 56.2%. HOKA is now guided to high-single-digit growth and UGG to low-single-digit. Deckers bought back $299M of stock in the quarter and has about $4.4B of authorization left.
.
| Metric | Data |
|---|---|
| Last close (derived) | About $85.30 (after-hours $78.22, -8.3%) |
| After-hours | About $78.22 (-7% to -8%) |
| 52-week range | $78.91 – about $126.50 |
| Market cap | About $12B |
| P/E | About 10.8x forward (guided EPS midpoint, includes refund) |
| Dividend | None |
| Volume vs. average | n/v |
| Q2 EPS / revenue | $2.31 vs. $1.80 est. / $1.481B vs. $1.51B est. |
| FY27 guidance | Revenue $5.70B – $5.725B; EPS $7.80 – $7.95 |
| Buyback | $299M in Q2; $637M in first half; $1.0B planned for the year |
| Analysts | Hold consensus (July: 9 Buy, 13 Hold, 2 Sell); average target about $119 |
| Support (S1 / S2 / S3) | $78.91 / $75 / $70 |
| Resistance (R1 / R2 / R3) | $85.30 / $90 / $100 |
Scenarios: Bullish: buyback demand holds $78.91 and reclaims $85. Base: a gap to $78 to $82 and basing. Bearish: a break of the 52-week low opens $75 and $70.
Bull case: A low forward multiple, a $1.0B buyback, strong margins and a pile of cash. Bear case: A revenue miss, a guide cut at both brands, weak direct sales and EPS flattered by a non-recurring refund.
What to watch:
- The reaction at the $78.91 52-week low
- Price-target cuts from analysts who set targets near $105 to $133
- Holiday-season commentary for UGG
Forecast: Holding $78.91 allows a bounce toward $85. A break likely tests $75.
Why this matters: Deckers is a read on the consumer, tariffs and premium footwear heading into the holidays.
4. Biohaven (BHVN) | Last Close About $15.10 (+27.8%) | FDA Accepts Vyglxia Resubmission
A Rejected Ataxia Drug Gets a Second Look, a Q1 2027 Date and a $48 Bull Target
Catalyst & latest news: The FDA accepted Biohaven’s resubmitted application for Vyglxia (troriluzole) in spinocerebellar ataxia, according to the company’s 8-K. The agency set a user-fee goal date in the first quarter of 2027 and plans an advisory committee meeting, with a date coming soon. The resubmission answers a November 2025 rejection. Separately, Biohaven signed a licensing deal with Ono Pharmaceutical worth $80M upfront and $20M in milestones.
Technicals: BioSpace reported shares at $15.41 by 10:40 a.m., 30% above the prior close of about $11.85, after a premarket spike of as much as 36%. The stock had slid from the mid-$13s into the high-$11s before the news.
Fundamentals: Biohaven has no product revenue. Its Q2 net loss was about $137M with operating cash burn near $85M, and long-term debt is roughly $260M. Baird raised its target to $48 and assigns a 50% chance of approval.
.
| Metric | Data |
|---|---|
| Last close / prior close | About $15.10 (+27.8%) / about $11.85 (derived) |
| Intraday high | About $16 (+36% premarket) |
| 52-week range | n/v |
| Market cap | n/v |
| P/E / Dividend | n/a (pre-revenue) / None |
| Volume vs. average | n/v |
| Q2 net loss / cash burn | About $137M / about $85M |
| Key dates | FDA goal date Q1 2027; advisory committee date to come |
| Deal | Ono license: $80M upfront, $20M milestone within a year |
| Analysts | Baird target $48 (50% approval probability) |
| Support (S1 / S2 / S3) | $13.50 / $11.85 / $10 |
| Resistance (R1 / R2 / R3) | $15.41 / $16 / $18 |
Scenarios: Bullish: a hold above $15 retests $16. Base: a gap-and-fade between $13.50 and $15.50. Bearish: a loss of $13.50 starts closing the gap to $11.85.
Bull case: A defined FDA timeline, non-dilutive Ono cash and a first-in-class label if approved. Bear case: The FDA rejected the drug before, an advisory panel adds a coin-flip event, and cash burn is heavy.
What to watch:
- The advisory committee date announcement
- Any equity raise after a 28% rally
- Analyst target changes toward Baird’s $48
Forecast: Holding $13.50 keeps $15.41 to $16 in play. A break points to $11.85.
Why this matters: Biohaven shows how a regulatory date can reprice a rejected drug in a single session.
5. Kaiser Aluminum (KALU) | Last Close About $118.15 (-23.3%) | Q3 Miss
Record Conversion Revenue Meets a 50% Sequential EBITDA Slide
Catalyst & latest news: Kaiser reported Q3 on Wednesday after the close, and the stock fell about 23% Thursday from $153.95. Adjusted EPS of $1.89 missed estimates of about $2.37 to $2.41. TIKR reported that operational problems, including a planned plant outage and start-up costs, cost about 6.4 points of margin and pushed 2026 EBITDA growth toward the low end of the 45% to 55% range.
Technicals: The stock at $120.67 midsession, and the close sits near $118. The stock had returned about 102% over the prior year, so the drop gave back a large share of it.
Fundamentals: Conversion revenue rose 25% to $439M and shipments hit 300M pounds. Adjusted EBITDA was $84M, up $3M year over year but down $82M from Q2 as metal-price tailwinds reversed, per the earnings call. Net debt was $933M (2.0x leverage), liquidity $687M, and Moody’s upgraded the company to Ba3 on Oct. 2.
.
| Metric | Data |
|---|---|
| Last close / prior close | About $118.15 (-23.3%, derived) / $153.95 |
| Midsession print | $120.67 (-21.6%) |
| 52-week range | n/v |
| Market cap | About $2.0B (derived) |
| P/E / Dividend | n/v / Yield about 2.7% |
| Volume vs. average | n/v |
| Performance | About +102% over 12 months before the drop |
| Q3 EPS / revenue | $1.89 adj. vs. about $2.37 – $2.41 est. / net sales $1.21B |
| Adj. EBITDA / margin | $84M / 19.1% (23.2% a year ago) |
| Balance sheet | Net debt $933M (2.0x); liquidity $687M |
| Analysts | n/v; expect target cuts at the open |
| Support (S1 / S2 / S3) | $115 / $105 / $100 |
| Resistance (R1 / R2 / R3) | $120.67 / $130 / $153.95 |
Scenarios: Bullish: demand and leverage buyers reclaim $120.67. Base: a sideways digestion between $112 and $122. Bearish: a break of $115 opens $105.
Bull case: Aerospace, packaging and engineering demand is strong, leverage is back in range and the miss traces largely to timing. Bear case: Margins compressed, outage and start-up costs continue into Q4 and a stock with a one-year gain of 102% had little cushion.
What to watch:
- Analyst target cuts and any rating changes
- Bellwood expansion cost commentary
- Whether $115 holds as support
Forecast: Holding $115 allows a bounce to $120 to $130. A break targets $105.
Why this matters: Kaiser shows how fast a momentum stock can unwind when execution, not demand, disappoints.
6. Robert Half (RHI) | Last Close $37.68 (+8.78%) | Earnings Beat, Up 9% to 10% More After Hours
The Staffing Firm Posts Its First Quarterly EPS Increase Since 2022
Catalyst & latest news: Robert Half reported Q3 EPS of $0.49, up 14% from $0.43 a year ago and ahead of the $0.47 estimate, on revenue of $1.359B that was flat on an adjusted basis and in line. Talent Solutions revenue grew 2% adjusted, its first increase since 2022, with U.S. Talent Solutions up 3% to $670M. Permanent placement revenue rose 6% for the quarter and 5% in September, per the earnings call summary. Q4 guidance is revenue of $1.29B to $1.39B and EPS of $0.36 to $0.46.
Technicals: RHI closed up 8.78% at $37.68 from $34.64, then gained another 9% to 10% after hours to roughly $41.20 to $41.51. At that level the stock trades near 89% of its $46.70 52-week high, after a weak month before the report.
Fundamentals: Adjusted operating income was $73M, a 5.3% margin versus 4.5% a year ago. Talent Solutions gross margin rose to 47.4% from 46.7%, operating cash flow was $66M and return on invested capital was 17%. Management said its AI spending targets candidate matching and outreach rather than immediate headcount cuts. Nine-month EPS of $0.90 is still below last year’s $1.01.
.
| Metric | Data |
|---|---|
| Last close / prior close | $37.68 (+$3.04, +8.78%) / $34.64 |
| After-hours | About $41.20 – $41.51 (+9% to +10%) |
| 52-week range | $21.83 – $46.70 |
| Market cap | About $3.8B at the close (100.9M diluted shares, derived) |
| P/E / Dividend | n/v / n/v |
| Volume vs. average | n/v |
| Performance | About +20% from Wednesday’s close at the after-hours price |
| Q3 EPS / revenue | $0.49 vs. $0.47 est. / $1.359B (flat adjusted) |
| Q4 guidance | Revenue $1.29B – $1.39B; EPS $0.36 – $0.46 |
| Margins | Adj. operating margin 5.3% (4.5% a year ago) |
| Analysts | n/v |
| Support (S1 / S2 / S3) | $37.68 / $34.64 / $32 |
| Resistance (R1 / R2 / R3) | $41.51 / $44 / $46.70 |
Scenarios: Bullish: a gap that holds $37.68 pushes toward $44. Base: an open near $40 to $41 that fades. Bearish: a failed gap loses $37.68 and revisits $34.64.
Bull case: Earnings growth has returned, hiring demand in U.S. Talent Solutions is firming and margins are widening. Bear case: Revenue is flat, the Q4 midpoint is below Q3 revenue, nine-month profit is still down and the stock could gain close to 20% in two sessions.
What to watch:
- Whether the gap above $37.68 holds in the first hour
- Analyst target and rating changes after the first EPS rise since 2022
- Friday’s read from other staffing and labor-market names
Forecast: Holding $37.68 keeps $41.51 to $44 in play. A fade loses $34.64.
Why this matters: Robert Half is a real-time gauge of white-collar hiring, which matters to the Fed meeting coming Oct. 27-28.
7. Lucid Diagnostics (LUCD) | Last Close $0.3334 (-1.71%) | Medicare Pays, $15M Raise, Up 30% to 58% After Hours
A $64 Million Cancer-Screening Stock Gets $1,938.01 a Test From Medicare and a Lifeline From Noteholders
Catalyst & latest news: Lucid said Medicare has begun paying for its EsoGuard esophageal DNA test at the established $1,938.01 fee-schedule rate. It also closed a $15M private placement of Series C convertible preferred stock on Oct. 21 with existing shareholders, including holders of a majority of its 12% secured notes due 2029. The preferred converts at $0.3519 per share, and noteholders acknowledged that Medicare payments addressed a Medicare-related default concern. Benzinga’s after-hours list showed the stock up about 42% to $0.46.
Technicals: LUCD closed at $0.3334, down 1.71%, and is down about 61% over the past month. After hours it traded between roughly $0.43 and $0.55, with about 32.7M shares changing hands and relative volume near 21x.
Fundamentals: Q2 revenue was $1.47M, up 17% from Q1, with a loss of $0.06 per share. The raise extends the cash runway, but the preferred carries dividend and liquidation preferences, and a resale registration is due within 120 days, so dilution is the trade-off. Penny-stock rules of the road are in TNN’s Oct. 16 stocks under $1 list.
.
| Metric | Data |
|---|---|
| Last close / prior close | $0.3334 (-1.71%) / about $0.339 (derived) |
| After-hours | About $0.43 – $0.55 (+30% to +58%) |
| 52-week range | n/v |
| Market cap | About $63.7M at the close; float about 152.6M shares |
| P/E / Dividend | n/a (loss-making) / None |
| Volume vs. average | About 32.7M after hours; relative volume near 21x |
| Performance | About -61% over one month |
| Q2 revenue / EPS | $1.47M (+17% sequentially) / -$0.06 |
| Financing | $15M Series C preferred; conversion price $0.3519 |
| Reimbursement | Medicare paying $1,938.01 per EsoGuard test |
| Analysts | n/v |
| Support (S1 / S2 / S3) | $0.33 / $0.30 / $0.25 |
| Resistance (R1 / R2 / R3) | $0.43 / $0.51 / $0.55 |
Scenarios: Bullish: follow-through above $0.43 targets $0.51 to $0.55. Base: a gap-and-fade between $0.35 and $0.45. Bearish: a loss of $0.33 erases the move.
Bull case: Medicare payments validate the reimbursement path, fresh cash buys time and the stock has fallen about 61% in a month. Bear case: Preferred stock converting near $0.35 caps rallies, revenue is tiny against heavy losses and sub-$1 stocks gap hard in both directions.
What to watch:
- Whether volume stays far above normal at the open
- Medicare claim volume and commercial payer updates
- The resale registration filing tied to the preferred
Forecast: Holding $0.33 keeps $0.43 to $0.51 in play. A fade under $0.33 points to $0.30.
Why this matters: Lucid is a small-cap test of whether reimbursement news can outrun the dilution that came with it.
8. Gentex (GNTX) | Last Verified Close $21.00 | Earnings Before the Open Friday
A Mirror Maker Hugging Its 52-Week Low, With a Goldman Sell and a Beat Streak to Defend
Catalyst & latest news: Gentex reports Q3 before the open Friday with a 9:30 a.m. ET call. Analysts expect EPS of $0.50 on revenue of about $670M, with EPS estimates spanning $0.48 to $0.54. Goldman Sachs downgraded the stock to Sell with a $20 target on Oct. 6, and UBS cut its target to $24 on Oct. 7.
Technicals: GNTX closed at $21.00 on Oct. 21, below its 50-day average near $22.58 and its 200-day near $23.32, and it is only about 2.5% above its 52-week low of $20.48. The stock is down about 7.8% year to date and 20% over 12 months. In July, an EPS beat was followed by a 3.7% drop because revenue missed.
Fundamentals: TradingView’s estimate history shows revenue missed in three of the last four quarters while EPS beat in each of the last three. Management guides 2026 revenue to $2.65B to $2.75B with gross margin of 34.5% to 35.5%, and 2027 revenue to $2.8B to $2.9B. Premium Audio grew 16% to $51.7M last quarter.
.
| Metric | Data |
|---|---|
| Last verified close | $21.00 (Oct. 21) |
| 52-week range | $20.48 – $26.99 |
| Market cap | About $4.4B |
| P/E (TTM) | About 11.1x (EPS $1.89, derived) |
| Dividend | $0.48 a year (about 2.3% yield) |
| Volume vs. average | n/v |
| Performance | YTD about -7.8%; 12-month about -20% |
| Beta | 0.82 |
| Q3 estimates | EPS $0.50 (range $0.48 – $0.54); revenue about $670M (+2.2%) |
| 2026 guidance | Revenue $2.65B – $2.75B; gross margin 34.5% – 35.5% |
| Analysts | Hold (1 Buy, 5 Hold, 1 Sell); average target $25.20 |
| Moving averages | 50-day about $22.58; 200-day about $23.32 |
| Support (S1 / S2 / S3) | $20.48 / $20 / $19 |
| Resistance (R1 / R2 / R3) | $21.50 / $22.58 / $23.32 |
Scenarios: Bullish: an EPS beat with firm guidance squeezes toward the 50-day near $22.58. Base: a 3% to 5% move either way around $21. Bearish: a revenue miss breaks $20.48 and tests $20.
Bull case: A low multiple, a 2.3% dividend, an EPS beat streak and 2027 guidance that implies growth. Bear case: Revenue misses, a Goldman Sell, a stock at its 52-week low and an automotive segment that shrank last quarter.
What to watch:
- Revenue versus about $670M, the line that has disappointed
- Any change to the $2.65B to $2.75B 2026 outlook
- Commentary on auto production and tariffs
Forecast: A beat holds $20.48 and targets $22.58. A revenue miss likely tests $20.
Why this matters: Gentex is a clean read on auto-supplier demand heading into a heavy week for industrial and auto earnings.
9. Booz Allen Hamilton (BAH) | Last Price About $78.57 | Earnings Before the Open Friday
A Federal Contractor at 12x Earnings Reports After a Year-Long Slide
Catalyst & latest news: Booz Allen reports fiscal Q2 before the open with an 8:00 a.m. ET call. MarketBeat lists consensus at EPS of $1.48 on revenue of $2.81B, against full-year guidance of $6.00 to $6.35 in EPS. The company has beaten EPS estimates 75% of the time over two years but met revenue estimates only 25% of the time.
Technicals: BAH was reported near $78.57 on Oct. 22, up from a $74.44 close on Oct. 16. It sits well above its spring low of $59.50 but about 19% below the roughly $97 level of a year ago.
Fundamentals: Trailing P/E is about 12.3, versus a five-year median near 24. The quarterly dividend is $0.59, and the payout ratio is about 35%. The Street expects revenue to fall about 3% year over year as federal spending pressure persists, and the average analyst target is $85.62 with a Hold consensus.
.
| Metric | Data |
|---|---|
| Last price | About $78.57 (Oct. 22, GuruFocus) |
| Prior reference close | $74.44 (Oct. 16) |
| 52-week range | $59.50 low; about $97 a year ago |
| Market cap | About $9.5B (derived) |
| P/E (TTM) | About 12.3 (five-year median about 24) |
| Dividend | $0.59 quarterly (about 3.0% yield) |
| Volume vs. average | n/v |
| Beta | 0.37 |
| Q2 estimates | EPS about $1.48 ($1.43 – $1.44 per Zacks); revenue $2.81B (-3.1%) |
| FY27 guidance | EPS $6.00 – $6.35 |
| Analysts | Hold; average target $85.62 |
| Support (S1 / S2 / S3) | $74.44 / $70 / $59.50 |
| Resistance (R1 / R2 / R3) | $80 / $85.62 / $90 |
Scenarios: Bullish: an EPS beat and steady guidance push through $80 toward the $85.62 average target. Base: a 4% to 6% move either way. Bearish: a guide cut or revenue miss loses $74.44.
Bull case: A low multiple, a 3% yield, a habit of EPS beats and a fresh start after a bruising year. Bear case: Shrinking revenue, revenue estimates missed three times out of four and a federal budget that keeps changing.
What to watch:
- Revenue and backlog versus the $2.81B estimate
- Any change to full-year EPS guidance
- Commentary on federal spending, AI and defense work
Forecast: A beat targets $80 to $85. A weak guide likely loses $74 and heads toward $70.
Why this matters: Booz Allen is the market’s read on federal technology spending, which ripples through defense and government IT names.
10. WISeSat.Space (SAIQ) | Last Close About $5.28 | Space Momentum, Up 18% After Hours
From $1.85 to $9.94 and Back: A Three-Week-Old Nasdaq Listing Trades Like a Rocket
Catalyst & latest news: SAIQ jumped as much as 35% Thursday to $7.53 on volume above 20M shares, with a morning high of $8.85, as cybersecurity headlines kept its satellite-security story in focus. Its FOSSASAT-2E27 satellite, which carries SEALSQ security technology, launched aboard a SpaceX Falcon 9. After hours the stock traded up about 18% at $6.25.
Technicals: SAIQ began trading Oct. 2 after merging with Columbus Acquisition, closed at $1.85 on day one and printed a $9.94 high on Oct. 5. It fell back to $3.41 on Oct. 19 and $5.56 on Oct. 21, then faded from Thursday’s $8.85 high to a close near $5.28 (derived from the after-hours quote).
Fundamentals: Revenue is tiny, and StocksToTrade put enterprise value near $94M earlier this week. The company is part of the WISeKey group, received a $10M investment from SEALSQ and is slated to help run a planned secure orbital cloud of up to 100 satellites through 2033, with the first payload targeted for Q4 2026.
.
| Metric | Data |
|---|---|
| Last close (derived) / prior close | About $5.28 / $5.56 |
| Intraday high | $8.85 (+59% over Wednesday’s close) |
| After-hours | About $6.25 (+18%) |
| 52-week range | $1.85 close on listing day; $9.94 high (Oct. 5) |
| Market cap | n/v (enterprise value near $94M earlier in the week) |
| P/E / Dividend | n/a / None |
| Volume vs. average | More than 20M shares by midday; average n/v |
| Performance | About +185% from the $1.85 listing-day close |
| Key catalysts | Satellite launch, SEALSQ $10M PIPE, orbital cloud plan |
| Analysts | n/v |
| Support (S1 / S2 / S3) | $5.28 / $4.50 / $3.41 |
| Resistance (R1 / R2 / R3) | $6.25 / $8.85 / $9.94 |
Scenarios: Bullish: an after-hours hold at $6.25 pushes back toward $8.85. Base: a wide, two-way range between $4.50 and $7. Bearish: a loss of $5.28 reopens $4.50 and the Oct. 19 close at $3.41.
Bull case: Space, cybersecurity and post-quantum themes, a small float and repeated momentum bursts. Bear case: Minimal revenue, dilution risk, a Thursday reversal from $8.85 to about $5.28 and a stock that has swung more than 400% in three weeks.
What to watch:
- Whether the after-hours bid near $6.25 survives the open
- Volume versus the 20M-plus shares traded Thursday
- Satellite or QSOC milestones from the WISeKey group
Forecast: Holding $5.28 keeps $6.25 to $7 in reach. A break likely heads to $4.50.
Why this matters: SAIQ shows how a new listing can add or erase half its value in a day, which is why position sizing matters more than the story.
Stocks to Watch Tomorrow: Sector Sentiment Snapshot and Forecast
| Group | Names | Sentiment | Driver |
|---|---|---|---|
| Software and communications | RNG | Constructive | Raised EPS guidance, AI revenue doubling |
| AI hardware and storage | WDC | Cautious | Beat and raise, but AI-trade selling |
| Consumer and footwear | DECK | Negative | Revenue miss, guide cut, tariff-flattered EPS |
| Metals and industrials | KALU | Bearish near term | Margin squeeze and a 23% drop |
| Staffing | RHI | Improving | First EPS increase since 2022 |
| Auto supplier and federal IT | GNTX, BAH | Event-driven | Friday pre-market earnings |
| Biotech and diagnostics | BHVN, LUCD | Speculative | FDA date, Medicare payments, dilution |
| Space micro-cap | SAIQ | Speculative | Momentum and a Thursday reversal |
Sector forecast: Friday opens with the Nasdaq at its weakest level since early June, so the first hour will show whether dip buyers or sellers win. The Dow’s flat close and falling Treasury yields favor rate-sensitive and defensive groups, while a Brent price above $110 keeps pressure on consumer and transport names. American Express, SLB, Gentex and Booz Allen all report before the bell, and the Fed meets Oct. 27-28 with Microsoft and Alphabet reporting Oct. 28. For the week’s earlier setups, see TNN’s Oct. 21 stocks to watch, Oct. 20 trending stocks and Oct. 19 stocks under $10.
Stocks to Watch Tomorrow: At a Glance
| # | Stock | Last Close | Move | Catalyst | Key Support | Key Resistance |
|---|---|---|---|---|---|---|
| 1 | RNG | $79.42 | -3.64% (AH about +14% to +15%) | Q3 beat, raised EPS guide | $83.72 | $91.50 |
| 2 | WDC | $354.19 | -6.43% (AH about -6%) | Beat, strong guide, AI-trade selloff | $331 | $354.19 |
| 3 | DECK | About $85.30 | AH about -7% to -8% | Revenue miss, guide cut | $78.91 | $85.30 |
| 4 | BHVN | About $15.10 | About +27.8% | FDA accepts Vyglxia resubmission | $13.50 | $15.41 |
| 5 | KALU | About $118.15 | About -23.3% | Q3 EPS miss | $115 | $120.67 |
| 6 | RHI | $37.68 | +8.78% (AH about +9% to +10%) | EPS beat, first rise since 2022 | $37.68 | $41.51 |
| 7 | LUCD | $0.3334 | -1.71% (AH about +30% to +58%) | Medicare payments, $15M raise | $0.33 | $0.43 |
| 8 | GNTX | $21.00 (Oct. 21) | n/v | Q3 earnings before the open | $20.48 | $21.50 |
| 9 | BAH | About $78.57 | n/v | Q2 earnings before the open | $74.44 | $80 |
| 10 | SAIQ | About $5.28 | AH about +18% | Space-security momentum | $5.28 | $6.25 |
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and small-cap, micro-cap, event-driven and high-volatility stocks carry elevated risk, including dilution, delisting and total loss. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change as trading continues. After-hours prices are indicative, and some closes are derived or unverified and labeled as such. Support and resistance levels are analytical zones, not predictions. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.
About The Author
